Erytech Pharma SA Financials

Erytech Pharma Stock Summary

Erytech Pharma competes with Genfit, HCW Biologics, Aptorum Group, Surrozen, and Unicycive Therapeutics. ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. The company was incorporated in 2004 and is headquartered in Lyon, France. Erytech Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.

Erytech Pharma Key Financial Ratios

Erytech Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Erytech Pharma's current stock value. Our valuation model uses many indicators to compare Erytech Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Erytech Pharma competition to find correlations between indicators driving Erytech Pharma's intrinsic value. More Info.Erytech Pharma SA is rated # 2 in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Erytech Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.